| Name | Title | Contact Details |
|---|
Aeglea was founded in December of 2013 to develop engineered human enzymes invented in the laboratory of George Georgiou, Ph.D. of The University of Texas at Austin. The convergence of discovery and technology has created a significant opportunity for Aeglea to potentially impact both the treatment of inborn errors of metabolism and cancer. Four drug candidates that degrade specific amino acids in the circulation are in development. For inborn errors of metabolism efforts are underway to normalize high arginine levels in patients who suffer from a gene mutation in the arginine degrading enzyme Arginase I and for patients who have mutations leading to excess levels of homocysteine. Taking advantage of a cancer’s metabolic vulnerability and selectively killing only the tumor through deprivation of arginine, cysteine/cystine, and methionine are techniques in development for multiple oncology indications. Coupling amino acid depletion therapy with the development of diagnostics for each oncology-focused enzyme creates a unique opportunity to potentially target the metabolic reprogramming of cancer with enhanced therapeutic benefit. At Aeglea, we believe we can lead the industry in modulating the extremes of amino acid metabolism in both cancers and certain inborn errors of metabolism, with the hope of improved outcomes for patients.
BioMarker Strategies is a Baltimore, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Home Advantage is a Herndon, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
EMD Biosciences is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
PDL manages a portfolio of patents and royalty assets, consisting of its Queen et al. patents, license agreements with various biotechnology and pharmaceutical companies, and royalty and other assets acquired. To acquire new income generating assets, PDL provides non-dilutive growth capital and financing solutions to late-stage public and private healthcare companies and offers immediate financial monetization of royalty streams to companies, academic institutions, and inventors. PDL has invested approximately $780 million to date. PDL evaluates its investments based on the quality of the income generating assets and potential returns on investment. PDL is currently focused on intellectual property asset management, acquiring new income generating assets and maximizing value for its shareholders. The Company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL was founded in 1986 and is headquartered in Incline Village, Nevada. PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases for which it receives significant royalty revenue.